By Fineline Cube 
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX’s investigational oncolytic virus product IVX037 combined with Innovent’s Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.
Expanded Partnership Details
The ongoing Phase Ib study, which is currently assessing the anti-tumor activity and tolerability of the combination therapy in advanced colorectal cancer, ovarian cancer, and gastric cancer, has been enrolling patients from 7 centers across Australia. According to the latest agreement, the study will add 15 liver cancer patients and is expected to include new study centers.
Initial Partnership and Background
Innovent and ImmVirX initially partnered in February 2022 to jointly investigate the combination therapy in clinical trials targeting advanced colorectal, ovarian, and gastric cancers. The expanded partnership now includes the evaluation of the combination in hepatocellular carcinoma, further broadening the scope of their collaborative efforts.-Fineline Info & Tech